Global Peptic Ulcers Treatment Market Size By Type (ASP-6537, BGC-001), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Peptic Ulcers Treatment Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 8.3 billion by 2031, expanding at a CAGR of 6.3% during the forecast period from 2023 to 2031. This growth is primarily attributed to the increasing prevalence of Helicobacter pylori (H. pylori) infections, rising use of nonsteroidal anti-inflammatory drugs (NSAIDs), and a growing aging population globally. Additionally, advancements in treatment options, including combination therapies and novel drug formulations, are further contributing to the market’s expansion.

Drivers:

1. Rising Incidence of H. pylori Infections:

A significant number of peptic ulcer cases globally are caused by H. pylori, a bacteria affecting the stomach lining. The increasing rate of infection, especially in developing regions with limited sanitation, is a key driver for the treatment market.

2. High NSAID Consumption:

Chronic use of NSAIDs for pain management in aging and arthritic populations increases the risk of ulcers, prompting the need for preventive and curative treatments.

3. Growing Geriatric Population:

The elderly are more susceptible to gastrointestinal disorders, including peptic ulcers, due to decreased mucosal defense and frequent use of multiple medications.

Restraints:

1. Side Effects and Drug Resistance:

Long-term use of proton pump inhibitors (PPIs) and antibiotics can lead to side effects and antimicrobial resistance, hindering treatment efficacy and market adoption.

2. Lack of Awareness in Low-Income Regions:

Inadequate healthcare infrastructure and awareness in some developing regions prevent early diagnosis and treatment, limiting market growth.

Opportunity:

1. Development of Advanced Therapies:

Opportunities lie in the development of novel drug delivery systems and targeted therapies that improve efficacy, reduce resistance, and minimize side effects.

2. Expansion into Emerging Markets:

Emerging economies with growing healthcare infrastructure and increased healthcare expenditure present untapped potential for market players.

Market by System Type Insights:

Based on system type, drug therapy remains the leading segment, driven by the effectiveness and widespread availability of proton pump inhibitors, H2-receptor antagonists, antacids, and antibiotics. However, the combination therapy segment is expected to witness the fastest growth, as it improves treatment success rates and reduces recurrence.

Market by End-Use Insights:

The hospital segment accounted for the largest market share in 2023 due to the availability of advanced diagnostic tools and treatment protocols. Meanwhile, the retail pharmacies segment is expected to grow steadily, supported by over-the-counter availability of acid-reducing medications and increased self-medication practices.

Market by Regional Insights:

In 2023, North America led the global peptic ulcers treatment market, fueled by high disease awareness, healthcare spending, and access to advanced therapeutics. Asia-Pacific is expected to register the fastest CAGR during the forecast period, driven by a large patient pool, rising H. pylori prevalence, and expanding healthcare infrastructure in countries like India and China.

Competitive Scenario:

Key players in the global market include Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Johnson & Johnson Services Inc., Eisai Co., Ltd., and Bayer AG. These companies are focusing on R&D, strategic collaborations, and expanding their product portfolios to address drug resistance and improve patient outcomes.

Scope of Work – Global Peptic Ulcers Treatment Market

Key Market Developments:

2023: AstraZeneca introduced a new fixed-dose combination therapy targeting both acid suppression and bacterial eradication, enhancing patient compliance.

2024: Pfizer collaborated with academic institutions to study resistance patterns in H. pylori for next-generation antibiotics.

2025: Takeda launched an extended-release formulation of a PPI aimed at reducing dosage frequency and improving adherence.

FAQs:

1) What is the current market size of the Global Peptic Ulcers Treatment Market?

The market was valued at USD 5.1 billion in 2023.

2) What is the major growth driver of the Global Peptic Ulcers Treatment Market?

The increasing prevalence of H. pylori infections and high NSAID consumption are key growth drivers.

3) Which is the largest region during the forecast period in the Global Peptic Ulcers Treatment Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Peptic Ulcers Treatment Market?

The drug therapy segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Peptic Ulcers Treatment Market?

Major players include Pfizer Inc., AstraZeneca plc, Takeda, GlaxoSmithKline, Novartis, and Johnson & Johnson.